神经鞘磷脂合成酶SMS1和SMS2在人乳腺癌组织中的表达及与病理的相关性  

Expression of sphingomyelin synthetase SMS1 and SMS2 in human breast cancer tissue and its correlation with pathology

作　　者：潘云青 PAN Yun-qing(Pathology Department,Nanyang Second General Hospital,Nanyang 473000,China)

机构地区：[1]南阳市第二人民医院病理科

出　　处：《临床医学研究与实践》2019年第32期124-125,共2页Clinical Research and Practice

摘　　要：目的探究神经鞘磷脂合成酶SMS1和SMS2在人乳腺癌组织中的表达及与病理的相关性。方法收集2015年1月至2018年6月乳腺癌组织及对应癌旁组织标本各50例,检测SMS1、SMS2表达水平,并分析其与临床病理参数的关系。结果乳腺癌组织中SMS1、SMS2阳性表达率均高于癌旁组织(P<0.05);多因素Logistic回归分析结果显示,分化程度、淋巴结转移是SMS1阳性表达的危险因素(P<0.05);临床分期、分化程度、淋巴结转移是SMS2阳性表达的危险因素(P<0.05)。结论 SMS1、SMS2在乳腺癌组织中高表达,可能参与乳腺癌的病情进展,且与分化程度及淋巴结转移相关。Objective To investigate the expression of sphingomyelin synthetase SMS1 and SMS2 in human breast cancer tissue and its correlation with pathology. Methods From January 2015 to June 2018, 50 samples of breast cancer tissues and corresponding adjacent tissues were collected. The expression of SMS1 and SMS2 were analyzed, and the relationship between them with clinicopathological parameters were analyzed. Results The positive expression rates of SMS1 and SMS2 in the breast cancer tissues were higher than those in the adjacent tissues(P <0.05). The multivariate Logistic regression analysis showed that differentiation and lymph node metastasis were the risk factors of positive expression of SMS1(P<0.05);the clinical stage, differentiation and lymph node metastasis were the risk factors of positive expression of SMS2(P<0.05). Conclusion SMS1 and SMS2 are highly expressed in the breast cancer tissues. It may be involved in the progress of breast cancer, and related to the degree of differentiation and lymph node metastasis.

关 键 词：神经鞘磷脂合成酶 乳腺癌 淋巴结转移 

分 类 号：R737.9[医药卫生—肿瘤]